Price Summary

FinStar

Ownership Stable

Ownership strength is slightly missing the benchmark.

ValuationExpensive

The stock is at a premium valuation at this point.

EfficiencyExcellent

The company knows very well the utilization of its assets.

FinancialsVery Stable

The company possesses stable growth history and manageable debt.

Company Essentials

Market Cap

14730.44 Cr.

Enterprise Value

15169.01 Cr.

Book Value (TTM)

₹  277.11

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

Azithral TELLZY ZEET Elena Corazon MEGACARE ZENOM CORIUM GASTRON ENTERON Maxis Ouron

 Group Companies

Ratios

Sales Growth

1 Year22.23%

3 Year19.7%

5 Year10.92%

Profit Growth

1 Year21.25%

3 Year40.7%

5 Year10.96%

ROE%

1 Year27.33%

3 Year28.08%

5 Year26.07%

ROCE %

1 Year26.5%

3 Year25.75%

5 Year26.52%

Interest Cover Ratio

111.931871574002

CFO/PAT (5 Yr. Avg.)

0.960356036379558

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2021 69.48 0
Mar 2021 69.48 0
Dec 2020 69.78 0
Sep 2020 69.77 0
Jun 2020 72.97 0

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
Net Sales 1258.43 1400.01 1235.77 1157.24 1269.69
Total Expenditure 835.09 943.86 864.01 836.25 992.72
Operating Profit 423.34 456.15 371.76 320.99 276.97
Other Income 0.16 2.84 2.7 4.03 1.74
Interest 6.09 2.33 2.21 2.14 2.03
Depreciation 35.84 36.71 38.21 41.84 43.49
Exceptional Items 0 0 0 0 0
Profit Before Tax 381.57 419.94 334.04 281.04 233.19
Tax 62.93 71.65 56.69 49.93 40.5
Profit After Tax 318.64 348.29 277.35 231.11 192.69
Adjusted EPS (Rs) 16.9 17.72 14.11 11.76 9.8

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Net Sales 2985.9 2945.26 3660.28 4132.56 5051.43
Total Expenditure 2353.36 2346.65 2800.98 2940.87 3553.18
Operating Profit 632.54 598.61 859.3 1191.69 1498.25
Other Income 3.28 40.59 25.79 145.96 83.72
Interest 3.21 2.22 14.87 25.19 12.77
Depreciation 82.9 101.76 105.59 135.67 152.6
Exceptional Items 0 0 0 -10 0
Profit Before Tax 549.71 535.22 764.63 1166.79 1416.6
Tax 119.08 113.23 153.42 197.39 241.21
Net Profit 430.63 421.99 611.21 969.4 1175.39
Adjusted EPS (Rs.) 22.85 22.39 32.42 51.43 59.8

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Equity and Liabilities
Share Capital 37.7 37.7 37.7 37.7 39.31
Total Reserves 1829.62 2156.93 2674.71 3308.32 5214.93
Borrowings 0 500 499.3 886.99 199.89
Other N/C liabilities 101 85.07 96.58 192.26 198.59
Current liabilities 658.79 1011.69 1397.76 1453.49 1123.46
Total Liabilities 2627.11 3791.39 4706.05 5878.76 6776.18
Assets
Net Block 799.01 918.3 1085.44 1276.46 1461.18
Capital WIP 347.75 740.64 1106.89 1569.98 1927.63
Intangible WIP 0 0 0 0 0
Investments 103.04 298.89 506.39 833.25 978.25
Loans & Advances 36.53 44.37 14.31 47.71 35.17
Other N/C Assets 0 0 0 0 0
Current Assets 1340.78 1789.19 1993.02 2151.36 2373.95
Total Assets 2627.11 3791.39 4706.05 5878.76 6776.18

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Profit from operations 549.71 535.22 764.63 1166.79 1416.6
Adjustment 84.88 81.9 91.48 30.14 61.78
Changes in Assets & Liabilities -189.44 -188.46 110.38 -460.39 247.36
Tax Paid -117.99 -124.11 -157.69 -196.79 -240.44
Operating Cash Flow 327.16 304.55 808.8 539.75 1485.3
Investing Cash Flow -510.97 -793.58 -753.67 -821.91 -926.47
Financing Cash Flow -96.06 497.8 79.67 166.13 -533.61
Net Cash Flow -279.87 8.77 134.8 -116.03 25.22

Corporate Actions

Super Investors

Investors Details

PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
Public 12.63 13.76 13.12 12.99 12.86
iepf 0.58 0.61 0.61 0.61 0
PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
FII/DII 14.4 16.46 17.1 17.53 17.66
elara india opportunities... 1.03 0 0 0 0
hdfc life insurance compa... 1.36 2.2 2.13 2.25 2.15
dsp mutual fund 0 1.96 1.7 2.02 1.89
dsp midcap fund 2.15 0 0 0 0
hdfc life insurance compa... 1.36 2.2 2.13 2.25 2.15
tata mutual fund 0 1.23 1.23 0 0
life insurance corporatio... 0 0 1.01 3.04 3.46
life insurance corporatio... 0 0 1.01 3.04 3.46
huf 0 0 0 0 0.27
llp 0 0 0 0 0.13

Alembic Pharma Stock Price Analysis and Quick Research Report. Is Alembic Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Alembic Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 1485.3 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Alembic Pharma has a Debt to Equity ratio of 0.0951 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Alembic Pharma , the EPS growth was 16.2832436594714 % which is good for the company.
     
  • Operating profit margin: It determines a companys potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Alembic Pharma has OPM of 29.6599180826024 % which is a good sign for profitability.
     
  • ROE: Alembic Pharma have a healthy ROE of 27.3338247913435 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholders fund is used for generating profits.
Brief about Alembic Pharma

Tell us about you

Find us at the office

Eastmond- Sukel street no. 62, 79540 Hanga Roa, Easter Island

Give us a ring

Jaquelinee Wrate
+74 201 709 645
Mon - Fri, 9:00-15:00

Reach out